AstraZeneca
The Executive Director, AI for Discovery leads AstraZeneca’s strategy to apply advanced AI and machine learning to accelerate oncology and biopharmaceutical discovery. This senior role guides a global team, integrates AI capabilities across the discovery ecosystem, and partners with scientific leadership to deliver AI‑enabled insights that improve biological understanding and increase technical success rates.
Headquarters
Cambridge, England, United Kingdom
Company Size
10001+ employees
Founded
1999
Digital Biology is part of AstraZeneca, a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines. The Digital Biology organization applies data science, computational biology, AI, and software engineering to accelerate drug discovery and translational research across therapeutic areas.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for AstraZeneca.
9% above the average for this role
Director, Search & Evaluation (Platforms & AI)
Novartis
Executive Director, Research – Technology & Innovation for Inflammation Discovery
Amgen
Senior AI Scientist – Drug Discovery & Computational Biology (Hybrid - Boston, MA, USA)
OMGTech
Postdoc, Autonomous Discovery & the AI Life Science Platform (2-year Fixed Term)
P&G
Principal Scientist, TechBio Discovery
Recursion
Chief Scientist, Modern Drug Discovery
lifelancer